JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients
Masroor, Mirza; Jain, Amit; Javid, Jamsheed; Mir, Rashid; Prashant, Y; Imtiyaz, A; Mariyam, Z; Mohan, Anant; Ray, PC; Saxena, Alpana;
  PDF(new window)
 Abstract
Background: NAD(P)H:quinone oxidoreductase 1 (NQO1) is part of the antioxidant defence system involved in detoxification. This study aimed to analyze the influence of NQO1 (C609T) genetic polymorphism in non small cell lung cancer (NSCLC)as a putative risk factor. Materials and Methods: Present study included 100 cases of NSCLC (adenocarcinoma) patients and 100 age and sex matched healthy controls. NQO1 (C609T) genotyping was performed by allele specific PCR for assessment of putative associations with clinical outcome and genotypes of. The association of the polymorphism with the survival of NSCLC patients` was analyzed by Kaplan-Meier method. Results: In Indian NSCLC (adenocarcinoma) patients increased risk of developing NSCLC was found to be associated with NQO1 609TT genotype [OR 3.68(0.90-14.98), RR 2.04(0.78-5.31)] for CT [OR 2.91(1.58-5.34), RR 1.74(1.23-2.44) p
 Keywords
NSCLC patients;adenocarcioma;NQO1 gene (C609T) polymorphism;AS-PCR;
 Language
English
 Cited by
1.
Association Between Polymorphisms of Metabolic Enzyme Genes and Chromosomal Damage in Benzene-Exposed Workers in China, Journal of Occupational and Environmental Medicine, 2017, 59, 11, e215  crossref(new windwow)
 References
1.
Anwar A, Dehn D, Siegel D, et al (2003). Interaction of human NAD (P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem, 278, 10368-73. crossref(new window)

2.
Asher G, Lotem J, Cohen B, et al (2001). Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA, 98, 1188-93. crossref(new window)

3.
Chao C, Zhang ZF, Berthiller J, et al (2006). NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87. crossref(new window)

4.
Chen H, Lum A, Seifried A, et al (1999). Association of the NAD (P) H: Quinone oxidoreductase 609CT polymorphism with a decreased lung cancer risk. Cancer Res, 59, 3045-8.

5.
Chen J, Lin Y, Zhang R, et al (2012). Contribution of NAD(P)H quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and risk of colorectal adenoma and colorectal cancer in Caucasians: a meta-analysis. Arch Med Res, 43, 58-66. crossref(new window)

6.
Guha N, Chang JS, Chokkalingam AP, et al (2008). NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol, 168, 1221-32.

7.
Hamajima N, Matsuo K, Iwata H, et al (2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.

8.
Haruya K, Nobuyuki H, Akiko T, et al (2003). Triplex polymerase chain reactions with confronting two-pair primers (PCR-CTPP) for NQO1 C609T, GSTM1 and GSTT1 polymorphisms: a convenient genotyping method.

9.
Hou L, Chatterjee N, Huang W, et al (2005). CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use and risk for colorectal adenoma. Carcinogenesis, 26, 1122-8. crossref(new window)

10.
Kolesar JM, Dahlberg SE, Marsh S, et al (2011). The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep, 25, 1765-72.

11.
Larson RA, Wang X, Banerjee M, et al (1999). Prevalence of the inactivating 609C to T polymorphism in the NAD(P) H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, 803-7.

12.
Lewis SJ, Cherry NM, Niven RM, et al (2001). Polymorphisms in theNAD( P)H: quinine oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177-83. crossref(new window)

13.
Mei-Miao C, Ying-Ju K, Ann-Ping T, et al (2009). Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma. Histol Histopathol, 24, 1223-32.

14.
Menashe I, Figueroa JD, Garcia-Closas M, et al (2012). Largescale pathwaybased analysis of bladder cancer genome-wide association data from five studies of European background. PLoS One, 7, 29396. crossref(new window)

15.
Nebert DW, Roe AL, Vandale SE, et al (2002). NAD (P) H:quinine oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 4, 62-70. crossref(new window)

16.
Ren JJ, OuYang XH, Su XL (2006). NAD (P)H:quinone oxidoreductase gene polymorphism association with gastric carcinoma. Zhong Hua Zhong liu Fang Zhi Za Zhi (in Chinese), 22, 1686-8.

17.
Ross D (2004). NQO1. Atlas genet cytogenet oncol haematol. URL : http://AtlasGeneticsOncology.org/Genes/NQO1ID375.html.

18.
Rosvold EA, McGlynn KA, Lustbader ED, et al (1995). Identification of an NAD (P) H: quinone oxidor - eductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199. crossref(new window)

19.
Sarmanova J, Susova S, Gut I, et al (2004). Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Gen, 12, 848-54. crossref(new window)

20.
Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9. crossref(new window)

21.
Siegel D, Anwar A, Winski SL, et al (2001). Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD (P)H:quinone oxidoreductase 1. Mol Pharmacol, 59, 263-8.

22.
Su XL, Yan MR, Yang L, et al (2012). NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia. Chin J Cancer Res, 24, 317-322. crossref(new window)

23.
Traver RD, Siegel D, Beall HD, et al (1997). Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75. crossref(new window)

24.
Wiemels JL, Pagnamenta A, Taylor GM, et al (1999). United Kingdom Childhood Cancer Study Investigators. A lack of a functional NAD(P)H: quinine oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res, 59, 4095-9.

25.
Xu LL, Wain JC, Miller DP, et al (2001). The NAD (P) H: quinone Oxidoreductase 1 Gene Polymorphism and Lung Cancer Differential Susceptibility Based on Smoking Behavior. Cancer Epidemiol Biomarkers Prev, 10, 303-9.

26.
Yuan W, Xu L, Chen W, et al (2011). Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat, 125, 467-72. crossref(new window)